Medtronic appoints new Operating Unit Presidents

  • Que Dallara joins as EVP & President, Diabetes
  • Mike Marinaro named President, Surgical Robotics
  • Dr. Kweli Thompson named President, Cardiac Rhythm Management

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units Diabetes, Surgical Robotics, and Cardiac Rhythm Management bringing in critical skills and capabilities and creating opportunities for internal talent.

"The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three Operating Unit President roles some of the most important and dynamic leadership opportunities in our industry," said Geoff Martha , Medtronic chairman and chief executive officer. "These appointments not only strengthen our businesses and build our technology expertise; they also further establish Medtronic as a destination for world-class talent."

Que Dallara joins as Executive Vice President and Operating Unit President, Diabetes
Que Dallara joins the Medtronic Executive Committee reporting to Chairman and CEO Geoff Martha on May 2, 2022 . Dallara comes from Honeywell where she served as President and CEO of Honeywell Connected Enterprise, and earlier as SVP and chief commercial officer. She also held general manager and strategy roles at TE Connectivity Ltd. and Microsoft, after working at McKinsey in her early career.

Experienced in new product development and commercialization, Dallara has managed robust product portfolios, led end-to-end R&D innovation, and business development initiatives that strengthened organic and inorganic company growth. She will bring unique and meaningful perspective and experiences to the Diabetes business and Medtronic Executive Committee.

In this role, Dallara succeeds Sean Salmon , executive vice president and president, Cardiovascular Portfolio and Diabetes Operating Unit, who now turns to focus exclusively on leading the Cardiovascular Portfolio. Salmon will ensure continuity and support Dallara's transition into the Diabetes business. He continues as a member of the Medtronic Executive and Capital Allocation Committees, helping to lead the company's enterprise strategy.

Mike Marinaro named Operating Unit President, Surgical Robotics
Marinaro joins the Medical Surgical Portfolio leadership team reporting to Executive Vice President and President, Bob White . Marinaro is a seasoned leader with more than 20 years of experience and success at Medtronic. Previously, he led the Cardiac Rhythm Management Operating Unit with annualized revenue of more than $4 billion . Under Marinaro's leadership, the business launched and scaled the Micra leadless pacemaker product line to more than $400 million annualized revenue.

Marinaro is known for his strong focus on innovation, commercialization, and scaling businesses and building inclusive work environments - ideal attributes to help continue Surgical Robotics' growth trajectory.

Marinaro succeeds Megan Rosengarten , who is taking a planned six-month sabbatical to spend more time with her family with the full support of Medtronic. Rosengarten has successfully led the Surgical Robotics business for the past four years, steering the Hugo RAS System from early development to commercialization, and leading the acquisition of the Digital Surgery business.

Dr. Kweli Thompson named Operating Unit President, Cardiac Rhythm Management
Dr. Thompson joins the Cardiovascular Portfolio leadership team reporting to Salmon. Dr. Thompson is an accomplished medical technology leader with two decades of experience in business development, clinical research, product marketing, and general management. Dr. Thompson is known for accelerating performance, growth, and profitability. Previously, as vice president and general manager of the Cardiac Resynchronization and Defibrillation Solutions businesses, a part of Cardiac Rhythm Management, he led Defibrillation Solutions to the highest market share in three years and the highest Cardiac Resynchronization Therapy market share in more than a decade.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com , and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Erika Winkels

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-8478

+1-763-505-4626

Que Dallara

Sean Salmon

Mike Marinaro

Dr. Kweli Thompson

(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-appoints-new-operating-unit-presidents-301504711.html

SOURCE Medtronic plc

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/March2022/17/c7712.html

News Provided by Canada Newswire via QuoteMedia

MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

2024 ATCO AGM (CNW Group/ATCO Ltd.)

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

Attendees will hear from:

  • Nancy Southern , Chair & Chief Executive Officer
  • Katie Patrick , Executive Vice President, Chief Financial & Investment Officer
  • Adam Beattie , President, ATCO Structures
  • Bob Myles , Chief Operating Officer, ATCO EnPower
  • Wayne Stensby , Chief Operating Officer, ATCO Energy Systems

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
Colin.Jackson@atco.com
(403) 808 2636

Media Inquiries:
Kurt Kadatz
Director, Corporate Communications
Kurt.Kadatz@atco.com
(587) 228 4571

SOURCE ATCO Ltd.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

-

PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic announces CMS national coverage analysis for Symplicity Spyral Renal Denervation System

  • National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
  • Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

"Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman , senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral. We appreciate CMS' efforts in creating new pathways to expedite access to breakthrough technologies like Symplicity Spyral and look forward to our continued partnership in developing a national coverage policy."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic announces CMS national coverage analysis for Symplicity Spyral Renal Denervation System

  • National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure
  • Milestone is supported by large public health need and robust, long-term data from the SPYRAL-HTN global clinical program

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. This national coverage analysis was initiated by CMS in response to Medtronic's request to support Medicare beneficiary access to the Symplicity™ Spyral renal denervation (RDN) system, used in the Symplicity blood pressure procedure.

"Hypertension is a global health epidemic that impacts a wide variety of patients," said Jason Weidman , senior vice president and president of the Coronary and Renal Denervation business within the Cardiovascular Portfolio at Medtronic. "As the leader in developing a minimally invasive treatment option for hypertension, Medtronic has been closely engaged with CMS to establish a national coverage pathway for Symplicity Spyral. We appreciate CMS' efforts in creating new pathways to expedite access to breakthrough technologies like Symplicity Spyral and look forward to our continued partnership in developing a national coverage policy."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic achieves CE Mark approval for BrainSense Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in- Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe including the UK.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic achieves CE Mark approval for BrainSense Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center. This landmark approval and first-in- Europe patient programming demonstrate significant advancements in personalized DBS therapy for people with Parkinson's in Europe including the UK.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×